Easel Biotechnologies, LLC, headquartered in the United States, is a pioneering force in the biotechnology industry, specialising in advanced gene editing and synthetic biology solutions. Founded in 2018, the company has rapidly established itself as a leader in the development of innovative tools for researchers and biopharmaceutical companies, focusing on enhancing the efficiency of genetic engineering processes.
Easel Biotechnologies offers a unique platform that streamlines the design and construction of DNA sequences, setting it apart from traditional methods. With a commitment to advancing scientific discovery, the company has achieved significant milestones, including collaborations with major research institutions and a growing portfolio of intellectual property. As a key player in the biotechnology sector, Easel Biotechnologies continues to drive innovation, positioning itself at the forefront of the gene editing landscape.
+50 vs industry average
Easel Biotechnologies, LLC’s score of 62 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Easel Biotechnologies, LLC?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Biodiesel Production is among the most carbon-intensive industries
Industry performance
The Biodiesel Production industry has increased its overall emissions by 76% since 2019
Reported emissions
No reported emissions data is available for Easel Biotechnologies, LLC yet.
Easel Biotechnologies, LLC's reported carbon emissions
Easel Biotechnologies, LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and initiatives.
As part of its corporate family relationship, Easel Biotechnologies inherits climate-related targets and performance metrics from Bristol-Myers Squibb Company. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded down from the parent organisation. However, specific reduction targets or achievements for Easel Biotechnologies are not detailed.
The absence of direct emissions data suggests that Easel Biotechnologies is still in the process of establishing its own climate strategy, potentially aligning with the broader sustainability goals set by Bristol-Myers Squibb. As the company develops its initiatives, it may adopt industry-standard climate terminology and practices to enhance its environmental impact and transparency.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Easel Biotechnologies, LLC’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Easel Biotechnologies, LLC yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Bristol-Myers Squibb Company
Carbon Disclosure Project
Inherited from Bristol-Myers Squibb Company
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Bristol-Myers Squibb Company
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Easel Biotechnologies, LLC yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project